



EXPRES²ION[®]

BIOTECH

DISCLAIMER:

THIS IS A NON-CERTIFIED TRANSLATION OF THE SWEDISH ORIGINAL DOCUMENT, WHICH PREVAILS.

Year-End Report

2018-01-01 – 2018-12-31

Expres²ion Biotech Holding AB

559033-3729

Conclusion of year-end report

“Expres²ion Biotech Holding AB” refers to Expres²ion Biotech Holding AB with corporate identity number 559033-3729. “The Company” or “Expres²ion” refers to the group, i.e. Expres²ion Biotech Holding AB and its fully owned operational subsidiary Expres²ion Biotechnologies ApS, Denmark.

Q4 (2018-10-01 to 2018-12-31)

- Group turnover amounted to 1,434 (1,823) KSEK.
- Result after financial items amounted to -6,104 (-4,124) KSEK.
- Net income amounted to -5,585 (-3,135) KSEK.
- Net income per share* amounted to -0.47 (-0.33) SEK.

The fiscal year 2018 (2018-01-01 to 2018-12-31)

- Group turnover amounted to 8,868 (9,795) KSEK.
- Result after financial items amounted to -18,853 (-11,750) KSEK.
- Net income amounted to -16,822 (-9,835) KSEK.
- Net income per share* amounted to -1.46 (-1.10) SEK.
- Cash flow from operating activities amounted to -12,879 (-8,608) KSEK
- Equity ratio** amounted to 39.6 (39.1) %.
- Cash and cash equivalents amounted to 6,255 (1,508) KSEK.

Numbers in parenthesis are the numbers from the same period in 2017.

*The Group’s net income per share: the net income for the period divided by 11,541,664, which is the average number of shares for the whole period. The average number of shares for the fourth quarter was 12,002,015. The total number of shares in Expres²ion Biotech Holding AB was 12,002,015 shares per 2018-12-31.

**Equity ratio: Shareholder’s equity divided by total capital.

Significant events during 2018

- On January 16, Expres²ion Biotech Holding AB announced that the Board decided, pursuant to the authorisation granted by an Extraordinary General Meeting, to carry out a preferential rights issue with the aim to accelerate the Company’s development. The preferential rights issue comprises a maximum of 2,400,403 shares with a subscription price of 8.00 SEK per share. Upon full subscription of the rights issue, Expres²ion will raise approximately MSEK 19.2 before issue expenses. The proceeds from the preferential rights issue are expected to finance Expres²ion’s possibilities to pursue additional projects regarding vaccines and candidate drugs that the Company regularly encounter on the market. In addition to this, the preferential rights issue will provide resources to create more value in the joint venture AdaptVac and its development projects. Finally, the preferential rights issue will finance further development of the Company’s platform with new products that will strengthen the Company’s position in new market segments and generate new clients, thereby increasing the Company’s short-term earnings as well as long-term possibilities.
- On February 1, Expres²ion Biotech Holding AB held an extraordinary general meeting. The report is available at the Company’s website (www.expres2ionbio.com).
- On March 2, Expres²ion Biotech Holding AB announced the outcome of the Company’s rights issue. The rights issue was subscribed at approximately SEK 30.3 million, corresponding to a subscription rate of approximately 158 percent. Through the rights issue, a total of 2,400,403 shares were issued and Expres²ion is provided approximately SEK 19.2 million before issuing costs.
- On April 20, Expres²ion Biotech Holding AB announced that their subsidiary’s U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first Expres²-based product. It was also stated that IBT is planning to launch approximately five products for research purposes annually, and that the collaboration is expected to generate annual revenues of up to 1 MSEK for Expres²ion, when fully implemented.
- On May 3, Expres²ion published its annual report for 2017. The annual report is available on Expres²ion’s website (www.expres2ionbio.com).

- On May 17, ExpreS²ion announced that the Company's patent application "Improved Protein Expression System", that covers the entire ExpreS² platform, has been approved in Canada.
- On May 24, the annual general meeting of ExpreS²ion Biotech Holding AB (publ) was held. The report is available on the Company's website (www.expres2ionbio.com).
- On May 29, the Company announced a collaboration agreement with GenIbet Biopharmaceuticals S.A. Regarding vaccine development and GMP manufacturing. The Board's assessment is that the agreement strengthens ExpreS²ion's position as a full-service provider from discovery up to early clinical development.
- On June 15, ExpreS²ion announced that the Company will present its malaria and breast cancer vaccine research at two scientific events in June 2018.
- On August 17, the Company announced that Bent U. Frandsen, currently VP of Business Development, has been appointed as Chief Business Officer (CBO). He will manage a proactive effort to substantially increase the customer base in the Company's vaccine development and production services segment.
- On August 17, the Company announced that a scientific article on the production of a malaria vaccine candidate using the Company's ExpreS² platform was published today in the journal *npj Vaccines*, a part of Nature Partner Journals Series. The article describes the production of the University of Oxford's leading blood-stage malaria vaccine candidate RH5.1 in accordance with GMP using the ExpreS² platform. The product met all criteria for sterility, purity and identity and the vaccine formulation was judged suitable for use in humans. RH5.1 is currently evaluated in a phase 1/2a clinical trial.
- On September 6, the Company announced that the Research & Commercial License Agreement with U.S.-based partner and licensee Integrated BioTherapeutics, Inc. ("IBT") had been amended to include own ExpreS²-based products, initially a number of Zika virus antigens.
- On September 10, the Company announced that its joint venture AdaptVac ApS ("AdaptVac") has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step forward for the project and documenting the patentability of the virus-like-particle (VLP) technology platform.
- On October 3, the Company announced that a recently published scientific article in *Nature Communications* on the Pfs48/45 malaria vaccine candidate adds further evidence to support that the ExpreS² platform is an excellent tool for producing transmission blocking malaria vaccines.
- On October 31, the Company announced that The Jenner Institute of the University of Oxford had presented positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using the ExpreS² platform, was shown to be safe and it is the first vaccine to demonstrate a reduction in the parasite multiplication rate following a blood-stage controlled human malaria infection. This is a very important milestone in a longstanding collaboration with The Jenner institute of Oxford and as stated by Professor Dr. Simon Draper, Leader of The Jenner Institute's Blood-Stage Malaria Vaccine Group, *"the encouraging results from this RH5.1 Phase I/IIa malaria study are in line with our preclinical findings and form a solid foundation on which to build the next steps in our blood-stage malaria vaccine clinical programme. We are grateful to ExpreS²ion for providing the enabling ExpreS² development and production platform, and their contribution to the project as a whole."*
- On December 12, ExpreS²ion announced the publication of the first visual image of the molecular 'key' the deadliest malaria parasite uses to enter human blood cells in the scientific journal *Nature*. The publication was authored by an international team, including scientists from ExpreS²ion, led by the Walter and Eliza Hall Institute of Medical Research ("WEHI"). This breakthrough will contribute to the development of vaccines based on a patent co-owned equally by WEHI and ExpreS²ion.
- On December 20, ExpreS²ion announced that the Company's joint venture AdaptVac ApS ("AdaptVac") has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs.

Significant events after the end of the period

- On January 10, 2019, ExpreS²ion announced that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS²ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS² platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.
- On February 19, 2019, ExpreS²ion announced that its joint venture AdaptVac has been awarded approx. SEK 3.6 million by the Danish Innovation Foundation for its participation in a vaccine project aimed at preventing post-weaning diarrhoea (PWD), a major cause of antibiotic use in the swine industry.

A word from our CEO Dr. Steen Klysner

We have now concluded the fiscal year of 2018, a period with a large number of positive news and continued strong development of the Company. I would like to take this opportunity to comment on some of the most important events during the year and present the management's view on the way forward for the Company.

In the fourth quarter of 2018, the Company's revenues were lower than expected, which we see as a consequence of the delayed effects from our new sales and marketing initiatives, as well as the increased focus on development activities. The lower revenues in combination with the investment costs are naturally reflected in the net result for 2018, which is not satisfying.

We do, however, believe that the value developed through targeted investment in new products and opportunities over the period exceeds the lack in revenues during the period. We thereby believe that we will be able to catch up on revenues in 2019, supported by a number of new products developed in 2018 for release in 2018/19, as well as additional service projects originating from our joint venture AdaptVac.



The rights issue at the beginning of the year

We started 2018 with the implementation of a rights issue, primarily in order to be able to handle more and larger projects, to develop new products, as well as to secure a strong development of AdaptVac. The rights issue received great interest and was oversubscribed, something we are of course proud of.

Our strategic projects

During and even after the year ending, we have been able to announce solid progress in several of the projects in which we are involved. In October, we published positive results from the phase I/IIa malaria vaccine study by the Jenner Institute of Oxford. The vaccine, which was developed and manufactured with our ExpreS2 platform, proved to be safe and it is the first vaccine to demonstrate a reduction in the parasitic growth following a controlled human malaria infection. This is an important step towards creating a malaria vaccine for wider large-scale use. For ExpreS2ion, this provided solid clinical validation of our core platform and brings us closer to an opportunity for future revenues if this is transferred to a commercial partner.

In December, we co-authored a publication in the scientific journal Nature, presenting first structure of a newly identified molecular "key" that malaria parasites use to enter human blood cells. This work is yet another exciting milestone in the research and design of new, effective vaccines for malaria in the blood phase and in this case made in collaboration with the renowned Australian Walter and Eliza Hall Institute (WEHI), with whom we have a 50% patent partnership. These achievements represent both significant potential value and a great commercial opportunity for ExpreS2ion, as the blood stage malaria market is valued at around USD 400 million annually.

In early January 2019, after the end of the period, the PlacMalVac consortium, of which we are part, published positive phase Ia clinical trial results from the placental malaria vaccine (PAMVAC) aiming at protection of pregnant women and their children. The vaccine, that was made using the ExpreS2 platform, was shown to be safe, well-tolerated and eliciting specific immune responses in all participants. This is encouraging news for the millions of pregnant women and their children, who are at risk of contracting placental malaria during pregnancy each year, and we are proud to be part of this team. This work is funded by several organisations, but as our platform is used both in the development and the manufacture of the PAMVAC vaccine, this project also has potential commercial value for ExpreS2ion, if partnered.

The platform

In 2018 we made targeted investments towards developing the core platform into a full discovery platform. This successfully led to a number of improvements and new products that the Company has introduced or will introduce in 2018/2019:

Platform development	Product development
✓ Increased production capacity	✓ R&D tools, U.S. distributor
✓ Two new core analytic instruments	✓ Formulation
✓ Strong in-licensed technology	✓ Advanced analytics
✓ Two patent applications submitted	✓ Immune enhancers
✓ Two strategic alliances	✓ New functional cell lines
✓ Two product partnerships	✓ New culture medium

We expect that this together with our updated marketing material, the webshop and added sales personnel will be an important driver of the planned expansion of the core business.

AdaptVac

In 2017, we established the joint venture company AdaptVac based on a ground-breaking new virus-like particle (VLP) technology. Since its initiation, the company has focused on improving and consolidating the proprietary technology by internal development as well as external collaborations and projects. One of AdaptVac's results so far was a Notice of Allowance in the U.S. in September for a patent covering its first project, the HER2 breast cancer vaccine project AV001. This is an extremely important milestone as it not only strengthens the Company's position and the sales value of the AV001 breast cancer project, but also for other HER2 relevant indications such as gastric and ovarian cancers and the platform in general.

In December, AdaptVac also received grants for two new projects: Cardiovascular disease and HER2-positive cancer in dogs. These contributions will finance the first important steps forward in AdaptVac's development of VLP-based vaccines for these indications in dogs, and the animal data generated in these studies will support and accelerate the development of similar products for human use, as well as strengthen the VLP platform. The inclusion of a cardiovascular disease vaccine project, which targets a USD 3 billion market in the AdaptVac portfolio, will potentially add significant value to the company. The co-development of an animal HER2-positive cancer project is a smart way to use existing knowledge to jump-start a veterinary project, that can be taken to the market much faster and generate value as well as animal safety and proof-of-concept data for the human studies without delaying them.

The way forward

In 2018 we focused on an expansion of our core platform by developing and including new technologies, as well as strengthening AdaptVac. We have succeeded well with these activities and have documented good progress in a number of existing and new projects at the same time. As we stated at the time of the rights issue, this required up-front investments in time as well as money, which is reflected in both revenues and costs for the year. We do, however, expect the revenues from our service business to improve markedly in 2019 when the effect of the improved platform and marketing activities kicks in. On the other hand, our investments in products and the development of AdaptVac in combination with the progress reported in other projects, values have been generated that by far exceeds the potential of the service business. Looking forward, we see the service business isolated reaching a sustainable plateau, whereas an increasing and highly exciting part of our activities will target the development of new and existing assets in partnerships and joint ventures, based on our optimised proprietary discovery platform.

Dr. Steen Klysner
CEO, ExpreS²ion Biotech Holding AB

About ExpreS²ion Biotech Holding AB

ExpreS²ion was established in 2010 as a spinout from the Danish pharmaceutical company Affitech A/S. The Company was founded by the doctors Charlotte Dyring, Wian de Jongh and Martin Roland Jensen, with the business idea to provide proteins to research institutions and vaccine producing companies, using a new platform technology. The Company's operations are based on the patent protected ExpreS² platform and its ability to produce complex proteins. The main component of the ExpreS² platform is S2 cells that can produce proteins, as well as the company's patented expression vectors, that are the part of the platform that, among other things, makes it possible for the cells to generate a high yield. The platform has a number of features that, according to the Board's assessment, distinguish it from competing technologies:

- It has on occasion been the only known method for producing specific proteins.
- It is significantly less costly and time-consuming than alternative methods, which is an important competitive advantage, considering for example time-to-market and patent validity, but it also makes the platform particularly valuable in the development of diagnostics and vaccines for infectious and rapidly growing pandemics.
- The method generates a significantly higher yield, i.e. amount of protein per manufacturing batch, compared to competing systems.
- The method provides very homogeneous manufacturing batches, which is a requirement in pharmaceutical development.


At this point the company already has a well-established and diverse customer base, as illustrated with selected examples in the figure below;



Business model and market potential

ExpreS²ion's business model consists of mainly three parts:


- ExpreS²ion can co-own pharmaceutical projects that use the ExpreS² platform. In this way, the Company can receive milestone payments as the development progresses as well as royalties in case the pharmaceutical or vaccine reaches market launch.
- ExpreS²ion can also market licenses to use the ExpreS² platform as a whole (or parts of it), thus allowing the client to participate in or be entirely responsible for the development of the proteins required for pharmaceutical or vaccine development. This is another way through which the Company can receive milestone payments and royalties for project development and market launch.



- The Company can also sell reagents and protein kits as well as charge clients for services where the Company develops tailor-made proteins and delivers these as finished products, using the ExpreS² platform.


The joint venture company AdaptVac

In addition to ExpreS²ion's core business activities described above, the Company initiated the joint venture AdaptVac ApS ("AdaptVac") in 2017 together with NextGen Vaccines ApS ("NextGen"), a company established by researchers from the University of Copenhagen. AdaptVac has a worldwide exclusive license to a plug and play virus like particle (VLP) technology, which enables accelerated development of efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. The aim of AdaptVac is to establish a world class company for the development of competitive vaccines and therapeutic treatments in this segment. The combination of ExpreS²ion's technology and know-how and NextGen's unique expertise within the VLP technology provides important synergy effects for ExpreS²ion's proprietary platform and has the potential to create a robust and versatile company within the field of new vaccines and immunotherapies. With AdaptVac, ExpreS²ion also enters the market for immuno-oncology which, according to Research and Markets 2018, is estimated to surpass a market value of USD 100 billion by 2022.



ExpreS²ion's project pipeline

The table below gives a brief description of the different projects that ExpreS²ion is currently involved in and in which the Company either holds a joint ownership or has outlicensed its platform. ExpreS²ion is currently involved in two projects in clinical phases. The first one is the RH5.1 blood-stage malaria vaccine conducted by the Jenner Institute of the University of Oxford to which ExpreS²ion has outlicensed its platform. Positive data from a phase I/IIa study within the project were communicated in October 2018. The other project in clinical phase is conducted by the PlacMalVac consortium and ExpreS²ion has a joint ownership in the project's development of a placental malaria vaccine. In this project, positive phase I data were communicated as late as January 2019. In addition to the projects described in the table below, the Company is also involved in a number of other non-disclosed projects.



Company structure and shareholding

ExpreS²ion Biotech Holding AB has a fully owned subsidiary, ExpreS²ion Biotechnologies ApS, in Denmark. All operational activity takes place in the subsidiary, and ExpreS²ion Biotech Holding AB's only operational activity is to own the subsidiary ExpreS²ion Biotechnologies ApS. In addition to this, ExpreS²ion Biotechnologies ApS owns 50 percent of the shares in AdaptVac ApS, Denmark. This company is accounted for as a jointly governed company. In addition to the above, the Company does not own any shares in other companies.

Development in figures for Q4 2018

Turnover

Group turnover during the fourth quarter 2018 amounted to KSEK 1,434 (1,823). Revenues come mainly from the development and production of reagents to customers. The revenue in Q4 2018 was 21% lower than for the same period last year. During the period, a number of targeted sales and marketing activities were made, including additional resources, update of materials and new digital initiatives. Due to the nature of our business with sale processes running over several months or longer, the effect of these new sales activities to the revenues is delayed. It is the expectation that the effect from these will have a positive impact on the revenue for 2019.

Result

Consolidated net result for the third quarter of 2018 amounted to KSEK -5,585 (-3,135). The net result is a consequence of the lower revenue as well as the increased costs for developing our platform and increased sales and marketing activities, which is expected to increase the Company's long-term revenues according to the Board.

Cash and cash equivalents

As of December 31, 2018, ExpreS²ion's cash and cash equivalents amounted to KSEK 6,255 (1,508), which reflects the share emission that was executed in March 2018 as well as the operating loss during the year.

Shareholder structure

The table below lists all shareholders who held more than 5% of the capital and voting shares in ExpreS²ion Biotech Holding AB as of December 31, 2018.

Name	Number of shares held	Share of votes and capital
ExpreS ² ion Holding ApS ¹	1 744 370	14.53 %
AR Consult ApS ²	1 397 003	11,64 %
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION	896 172	7,47 %
Ericsson, Anders	699 026	5,82 %
Summary shareholders over 5 %	4 736 571	39,46 %
Remaining shareholders (below 5 %)	7 265 44	60,54 %
Total 31/12/2018	12,002,015	100,00%

- ¹Chairman of the board Martin Roland Jensen holds 32.22% of the voting and capital shares in ExpreS²ion Holding ApS. COO Charlotte Dyring owns 39.23% of the voting and capital shares in ExpreS²ion Holding ApS. CSO Wian de Jongh owns 28.55% of the voting and capital shares in ExpreS²ion Holding ApS.
- ²Board member Allan Rosetzky owns 100% of the shares in AR Consult ApS.

The share

ExpreS²ion Biotech Holding AB's share was listed at Nasdaq Stockholm First North on July 29, 2016. The trading name of the share is EXPRS2 and the ISIN-code is SE0008348262. As of January 1, 2018, the number of shares in ExpreS²ion Biotech Holding AB amounted to 9,601,612. As of December 31, 2018, the number of shares in ExpreS²ion Biotech Holding AB amounted to 12,002,015. The average amount of shares for the whole of 2018 amounted to 11,541,664. The average amount of shares for the fourth quarter 2018 amounted to 12,002,015. There is one single class of shares in the Company. All shares carry equal rights to a share of the Company's assets and earnings.

Operational risks and uncertainties

The risks and uncertainties that ExpreS²ion's operations are exposed to are summarised in terms of pharmaceutical development, competition, technology development, patents, government requirements, capital requirements, currencies and interest rates. During the current period, no significant changes regarding risk or uncertainty factors have occurred. For

more detailed reporting of risks and uncertainties, refer to the previously published memorandum, published in February 2018, and the Company's annual report for the fiscal year of 2017.

Auditor review

This year-end report has not been formally reviewed by the Company's auditor.

Proposed appropriation of retained earnings

The Board and the CEO have proposed that no dividend be paid for the accounting year 2018-01-01 – 2018-12-31.

Annual General Meeting and availability of the Annual Report

ExpreS²ion Biotech Holding AB's Annual General Meeting will be held on the Company's address in Helsingborg on May 23, 2019. The annual report will be available for downloading on ExpreS²ion Biotech Holding AB's website (<http://www.expres2ionbio.com/investor/reports-presentations/>) no later than three weeks before the annual general assembly.

Accounting principles

ExpreS²ion Biotech Holding AB applies the Swedish Annual Accounts Act and Swedish Accounting Standards Board's general standard BFNAR 2012:1 when preparing its financial statements.

Financial calendar

Interim report Q1, 2019	2019-05-16
Annual General Meeting, 2019	2019-05-23
Half year report, 2019	2019-08-22
Interim report Q3, 2019	2019-11-21
Year-end report, 2019	2020-02-28

Certified Adviser

Sedermera Fondkommission

Email: CA@sedermera.se

Telephone: +46 40-615 14 10

For more information, please contact

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

Email: sk@expres2ionbio.com

The Board of Directors and the CEO indicates that the Year-end report presents a fair view of ExpreS²ion Biotech Holding AB's business.

Hørsholm, February 28, 2018
ExpreS²ion Biotech Holding AB
c/o Mazars SET, Terminalgatan 1, 252 24 Helsingborg, Sverige

Board of Directors and CEO

Financial overview

Income statement in brief – group

KSEK	2018-10-01	2017-10-01	2018-01-01	2017-01-01
	2018-12-31	2017-12-31	2018-12-31	2017-12-31
	3 months	3 months	12 months	12 months
Net sales	1,435	1,823	8,868	9,795
Raw materials and consumables	- 383	- 576	- 2,753	- 2,193
Gross earnings	1,052	1,247	6,115	7,602
Other external costs	- 1,823	- 1,089	- 7,176	- 5,928
Personnel costs	- 4,160	- 3,289	- 13,253	- 10,319
Result in jointly governed companies	- 288	- 477	- 1,327	- 509
Operating profit/loss before depreciation	- 5,219	- 3,608	- 15,641	- 9,154
Depreciation	- 682	- 581	- 2,615	- 2,281
Operating profit/loss	- 5,901	- 4,189	- 18,256	- 11,435
Other financial income	20	146	20	146
Other financial costs	- 223	- 81	- 617	- 461
Profit/loss from financial items	- 203	65	- 597	- 315
Profit/loss before tax	- 6,104	- 4,124	- 18,853	- 11,750
Tax	519	989	2,031	1,915
Profit/loss for the period	- 5,585	- 3,135	- 16,822	- 9,835

Balance sheet in brief – group

KSEK	2018-12-31	2017-12-31
Assets		
Concessions, patents, licenses, trademarks and similar intellectual rights	7,030	8,241
Goodwill	1,383	1,900
Total intangible fixed assets	8,413	10,141
Other tangible assets	993	632
Total tangible assets	993	632
Interest in group companies	34	0
Other long-term receivables	682	408
Financial assets	716	408
Total fixed assets	10,122	11,181
Accounts receivable	1,317	1,086
Tax receivables	1,757	1,478
Other receivables	975	1,331
Receivables from group companies	0	315
Prepaid expenses	528	336
Total receivables	4,577	4,546
Cash and cash equivalents	6,255	1,508
Total current assets	10,832	6,054
TOTAL ASSETS	20,954	17,235
Equity and liabilities		
Share capital	1,334	1,067
Other capital contributions	41,803	23,815
Other equity including net profit for the period	- 34,836	-18,145
Total equity	8,301	6,737
Accrued tax liabilities	1,546	1,813
Total liabilities	1,546	1,813
Other long-term liabilities	6,063	6,324
Total long-term liabilities	6,063	6,324
Liabilities to credit institutions	924	75
Accounts payable	607	470
Other liabilities	3,513	1,816
Total contingent liabilities	5,044	2,361
Total liabilities	12,653	10,498
TOTAL EQUITY AND LIABILITIES	20,954	17,235

Cash flow statement in brief – group

KSEK	2018-10-01	2017-10-01	2018-01-01	2017-01-01
	2018-12-31	2017-12-31	2018-12-31	2017-12-31
	3 months	3 months	12 months	12 months
Operating profit/loss	- 5,901	- 4,189	- 18,256	- 11,435
Adjustments for depreciation	682	581	2,615	2,281
Other non-cash adjustments	-34	0	- 34	0
Received interest	78	52	78	91
Interest paid	- 111	- 218	- 602	- 581
Company tax paid	1,478	1,285	1,471	1,262
Cash flow from operating activities before changes in working capital	- 3,808	- 2,489	- 14,728	- 8,382
Decrease / increase of current receivables	- 664	171	- 228	1,446
Decrease / increase of current liabilities	1,283	- 300	2,077	- 1,672
Cash flow from operating activities	- 3,189	- 2,618	- 12,879	- 8,608
Investments in tangible fixed assets	- 276	- 77	- 813	- 206
Cash flow from investing activities	- 276	- 77	- 813	- 206
Leasing agreement	- 51	50	328	380
Redemption of options	0	79	58	79
Issuance of new shares	0	0	19,203	3,928
Costs of issuing shares	0	0	- 1,003	- 402
Cash flow from financing activities	- 51	129	18,586	3,985
Cash flow for the period	- 3,516	- 2,566	4,894	- 4,829
Cash and cash equivalents at the beginning of the period	9,758	3,972	1,508	6,258
Exchange difference cash and cash equivalents	13	102	- 147	79
Cash and cash equivalents at the end of the period	6,255	1,508	6,255	1,508

Changes in equity in brief – group

KSEK	2018-10-01	2017-10-01	2018-01-01	2017-01-01
	2018-12-31	2017-12-31	2018-12-31	2017-12-31
	3 months	3 months	12 months	12 months
Total equity at the beginning of the period	13,827	9,738	6,737	12,880
Issuance of new shares	0	0	19,203	3,928
Redemption of options	0	79	58	79
Issuing cost	0	0	- 1,003	- 402
Profit/loss for the period	- 5,585	- 3,135	- 16,822	- 9,835
Exchange difference	59	55	128	87
Total equity at the end of the period	8,301	6,737	8,301	6,737

Income statement in brief – parent company

KSEK	2018-10-01	2017-10-01	2018-01-01	2017-01-01
	2018-12-31	2017-12-31	2018-12-31	2017-12-31
	3 months	3 months	12 months	12 months
Net sales	246	189	335	305
Other external costs	- 517	- 572	- 2,089	- 1,859
Personnel costs	- 124	- 104	- 454	- 234
Operating profit/loss before depreciation	- 395	- 487	- 2,208	- 1,788
Depreciation	0	0	0	0
Operating profit/loss	- 395	- 487	- 2,208	- 1,788
Other financial income	200	55	608	83
Other financial costs	- 5	- 2	- 5	- 5
Profit/loss from financial items	195	53	603	78
Profit/loss before tax	- 200	- 434	- 1,605	- 1,710
Tax	0	0	0	0
Profit/loss for the period	- 200	- 434	- 1,605	- 1,710

Balance sheet in brief – parent company

KSEK	2018-12-31	2017-12-31
Assets		
Deposits	50	50
Shares in group companies	17,496	17,496
Receivables from group companies	15,768	4,099
Total financial fixed assets	33,314	21,645
Total fixed assets	33,314	21,645
Tax receivables	14	15
Other receivables	45	202
Prepaid expenses	30	71
Total receivables	89	288
Cash and cash equivalents	5,790	214
Total current assets	5,879	502
TOTAL ASSETS	39,193	22,147
Equity and liabilities		
Share capital	1,334	1,067
Share premium account	40,636	22,645
Net profit/loss for the period	-3,315	-1,710
Total equity	38,655	22,002
Other liabilities	538	145
Total contingent liabilities	538	145
Total liabilities	538	145
TOTAL EQUITY AND LIABILITIES	39,193	22,147

Cash flow statement in brief – parent company

KSEK	2018-10-01	2017-10-01	2018-01-01	2017-01-01
	2018-12-31	2017-12-31	2018-12-31	2017-12-31
	3 months	3 months	12 months	12 months
Operating profit/loss	- 395	- 487	- 2,208	- 1,788
Received interest	16	0	16	0
Interest paid	- 17	- 2	- 21	- 5
Company tax paid	8	26	1	3
Cash flow from operating activities before changes in working capital	- 388	- 463	- 2,212	- 1,790
Decrease / increase of current receivables	54	- 119	195	- 134
Decrease / increase of current liabilities	93	- 108	394	- 308
Cash flow from operating activities	- 241	- 690	- 1,623	- 2,232
Loans group Company	311	613	- 11,059	- 3,971
Cash flow from investing activities	311	613	- 11,059	- 3,971
Issuance of new shares	0	0	19,203	3,928
Redemption of options	0	79	58	79
Costs of issuing shares	0	0	- 1,003	- 402
Cash flow from financing activities	0	79	18,258	3,605
Cash flow for the period	70	2	5,576	- 2,598
Cash and cash equivalents at the beginning of the period	5,720	212	214	2,812
Cash and cash equivalents at the end of the period	5,790	214	5,790	214

Changes in equity – parent company

KSEK	2018-10-01	2017-10-01	2018-01-01	2017-01-01
	2018-12-31	2017-12-31	2018-12-31	2017-12-31
	3 months	3 months	12 months	12 months
Total equity at the beginning of the period	38,855	22,357	22,002	20,107
Issuance of new shares	0	0	19,203	3,928
Redemption of options	0	79	58	79
Issuing cost	0	0	- 1,003	- 402
Profit/loss for the period	- 200	- 434	- 1,605	- 1,710
Total equity at the end of the period	38,655	22,002	38,655	22,002



EXPRES²ION[®]

BIOTECH

Agern Allé 1, DK-2970 Hørsholm, Denmark
www.expres2ionbio.com